Moxonidine

Identification

Name

Moxonidine

Accession Number

DB09242

Type

Small Molecule

Groups

Approved, Investigational

Description

Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Moxonidine (DB09242)

×

Close

Synonyms

• (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid
• Moxonidina
• Moxonidine
• Moxonidinum

External IDs

BDF-5896 / BDF5896 / BE 5895 / BE5895 / LY-326869 / LY326869

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Moxonidine hydrochloride	5RYW07SK5E	75438-58-3	ZZPAWQYZQVUVHX-UHFFFAOYSA-N

International/Other Brands

Cynt / Physiotens (Solvay Pharmaceuticals)

Categories

• Adrenergic Agonists
• Adrenergic alpha-2 Receptor Agonists
• Adrenergic alpha-Agonists
• Agents producing tachycardia
• Agents that produce hypertension
• Antiadrenergic Agents, Centrally Acting
• Antihypertensive Agents
• Cardiovascular Agents
• Hypotensive Agents
• Imidazoline Receptor Agonists
• Sympatholytics

UNII

CC6X0L40GW

CAS number

75438-57-2

Weight

Average: 241.677
Monoisotopic: 241.073037738

Chemical Formula

C₉H₁₂ClN₅O

InChI Key

WPNJAUFVNXKLIM-UHFFFAOYSA-N

InChI

InChI=1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)

IUPAC Name

4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine

SMILES

COC1=NC(C)=NC(Cl)=C1NC1=NCCN1

Pharmacology

Indication

For the treatment of mild to moderate essential or primary hypertension ⁷. Effective as most first-line antihypertensives when used as monotherapy ².

Pharmacodynamics

Antihypertensive agent whose site of action is the Central Nervous System (CNS), specifically involving interactions with I1- imidazoline and alpha-2-adrenergic rececptors within the rostral ventrolateral medulla (RSV). ^Label

Mechanism of action

Stimulation of central alpha 2-adrenergic receptors is associated with sympathoadrenal suppression and subsequent reduction of blood pressure. As this class was further explored it was discovered that sympathoadrenal activity can also be suppressed by a second pathway with a newly discovered drug target specific to imidazolines ⁵. Specifically, moxonidine binds the imidazoline receptor subtype 1 (I1) and to a lesser extent αlpha-2-adrenoreceptors in the RSV causing a reduction of sympathetic activity, reducing systemic vascular resistance and thus arterial blood pressure. ^Label

Moreover, since alpha-2-adrenergic receptors are considered the primary molecular target that facilitates the most common side effects of sedation and dry mouth that are elicited by most centrally acting antihypertensives, moxonidine differs from these other centrally acting antihypertensives by demonstrating only low affinity for central alpha-2-adrenoceptors compared to the aforementioned I1-imidazoline receptors ^Label.

Target	Actions	Organism
AAlpha-2A adrenergic receptor	agonist	Humans
ANischarin	agonist	Humans

Absorption

90% of an oral dose is absorbed with negligible interference from food intake or first pass metabolism, resulting in a high bioavailability of 88%. ^Label

Volume of distribution

1.8±0.4L/kg. ^Label

Protein binding

About 10% of moxonidine is bound to plasma proteins. ^Label

Metabolism

Biotransformation is unimportant ³ with 10-20% of moxonidine undergoing oxidation reactions to the primary 4,5-dehydromoxonidine metabolite and a guanidine derivative by opening of the imidazoline ring. ^Label

The antihypertensive effects of these 4,5-dehydromoxonidine and guanidine metabolites are only 1/10 and 1/100 the effect of moxonidine ^Label.

Oxidation on either the methyl group (pyrimidine ring) or on the imidazole ring of moxonidine results in the formation of the hydroxylmethyl moxonidine metabolite or the hydroxy moxonidine metabolite ⁶. The hydroxy moxonidine metabolite can be further oxidized to the dihydroxy metabolite or it can lose water to form the dehydrogenated moxonidine metabolite, which itself can be further oxidized to form an N-oxide ⁶. Aside from these Phase I metabolites, Phase II metabolism of moxonidine is also evident with the presence of a cysteine conjugate metabolite minus chlorine ⁶. Nevertheless, the identification of the hydroxy moxonidine metabolite with a high level of dehydrogenated moxonidine metabolite in human urine samples suggests that dehydrogenation from the hydroxy metabolite to the dehydrogenated moxonidine metabolite represents the primary metabolic pathway in humans ⁶.

The cytochromes P450 responsible for the metabolism of moxonidine in humans have not yet been determined ⁶.

Ultimately, the parent moxonidine compound was observed to be the most abundant component in different biological matrices of urinary excretion samples, verifying that metabolism only plays a modest role in the clearance of moxonidine in humans ⁶.

Route of elimination

Elimination is nearly entirely via the kidneys with a majority (50 -75%) of overall moxonidine being eliminated unchanged through renal excretion. Ultimately, more than 90% of a dose is eliminated by way of the kidneys within the first 24 hours after administration, with only approximately 1% being eliminiated via faeces. ^Label

Half life

Plasma elimination half life is 2.2 - 2.3 hours while renal elimination half life is 2.6-2.8 hours. ^Label

Clearance

Administered twice daily due to short half life ^Label.

However, lower dosage adjustments and close monitoring is necessary in elderly and renal impairment patients due to reduced clearance. In particular, the exposure AUC can increase by about 50% following a single dose and at steady state in elderly patients and moderately impaired renal function with GFR between 30-60 mL/min can cause AUC increases by 85% and decreases in clearence to 52 %. ^Label

Toxicity

• Contraindicated due to known hypersensitivity to an ingredient (Physiotens tablets contain lactose), heart failure, severe renal impairment, < 16 years old, >75 years old, bradycardia, severe bradyarrhythmia, sick sinus syndrome, second or third degree atrioventricular block, malignant arrhythmias. ^Label
• Used with caution in patients with history of severe coronary artery disease (CAD), unstable angina, angioneurotic edema. ^Label
• Pregnancy Category B3:Avoid use during pregnancy (inadequate data in pregnant woman) and lactation (maternal blood stream transfer to breast milk shown) unless benefit clearly justifies risk. ^Label
• Lack of specific therapeutic experience in cases of intermittent claudication, Raynaud's disease, Parkinson's disease, epileptic disorders, gluacoma, and depression suggest moxonidine should not be used in such instances ^Label.
• Carcinogenicity and genotoxicity does not appear significant. ^Label
• Concurrent administration of other hypotensives or sedative and hypnotics can enhance the hypotensive effect and intensify sedation respectively. ^Label
• Avoid concurrent Tricyclic Antidepressant (TCA) use to avoid reduction of monoxidine efficacy. ^Label
• Generally well tolerated with dry mouth and headache the most common adverse effects ^Label
• Symptoms of overdose correlate with pharmacodynamic properties:hypotension, sedation, orthostatic dysregulation, bradycardia, dry mouth with no specific counter-treatment known. ^Label

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• All Drugs
• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental

Drug	Interaction
Unlock Additional Data
1-benzylimidazole	The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Moxonidine.
2,5-Dimethoxy-4-ethylamphetamine	The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Moxonidine.
2,5-Dimethoxy-4-ethylthioamphetamine	The risk or severity of hypertension can be increased when Moxonidine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine	The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Moxonidine.
4-Methoxyamphetamine	The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Moxonidine.
5-methoxy-N,N-dimethyltryptamine	The risk or severity of hypertension can be increased when Moxonidine is combined with 5-methoxy-N,N-dimethyltryptamine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Moxonidine.
Abediterol	The risk or severity of hypertension can be increased when Moxonidine is combined with Abediterol.
Acebutolol	The therapeutic efficacy of Moxonidine can be decreased when used in combination with Acebutolol.
Aceclofenac	The therapeutic efficacy of Moxonidine can be decreased when used in combination with Aceclofenac.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

Not Available

References

General References

1. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003 Oct;5(5):659-67. [PubMed:14607206]
2. Fenton C, Keating GM, Lyseng-Williamson KA: Moxonidine: a review of its use in essential hypertension. Drugs. 2006;66(4):477-96. [PubMed:16597164]
3. Prichard BN, Owens CW, Graham BR: Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. J Hum Hypertens. 1997 Aug;11 Suppl 1:S29-45. [PubMed:9321737]
4. Prichard BN, Graham BR: I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Drugs Aging. 2000 Aug;17(2):133-59. [PubMed:10984201]
5. Ernsberger P, Haxhiu MA, Graff LM, Collins LA, Dreshaj I, Grove DL, Graves ME, Schafer SG, Christen MO: A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist. Cardiovasc Drugs Ther. 1994 Mar;8 Suppl 1:27-41. [PubMed:8068578]
6. He MM, Abraham TL, Lindsay TJ, Schaefer HC, Pouliquen IJ, Payne C, Czeskis B, Shipley LA, Oliver SD, Mitchell MI: Metabolism and disposition of the antihypertensive agent moxonidine in humans. Drug Metab Dispos. 2003 Mar;31(3):334-42. [PubMed:12584161]
7. Electronic Medicines Compedium Physiotens (Moxonidine) Monograph [Link]

External Links

Human Metabolome Database

HMDB0041938

KEGG Drug

D05087

KEGG Compound

C07451

PubChem Compound

4810

PubChem Substance

310265145

ChemSpider

4645

BindingDB

50050093

RxNav

30257

ChEBI

7009

ChEMBL

CHEMBL19236

ZINC

ZINC000001854466

Wikipedia

Moxonidine

ATC Codes

C02AC05 — Moxonidine

• C02AC — Imidazoline receptor agonists
• C02A — ANTIADRENERGIC AGENTS, CENTRALLY ACTING
• C02 — ANTIHYPERTENSIVES
• C — CARDIOVASCULAR SYSTEM

C02LC05 — Moxonidine and diuretics

• C02LC — Imidazoline receptor agonists in combination with diuretics
• C02L — ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
• C02 — ANTIHYPERTENSIVES
• C — CARDIOVASCULAR SYSTEM

FDA label

Download (108 KB)

MSDS

Download (56.5 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Not Yet Recruiting	Other	Postural Tachycardia Syndrome	1
0	Suspended	Other	Postural Tachycardia Syndrome	1
1	Not Yet Recruiting	Basic Science	Obesity-Associated Insulin Resistance	1
3	Completed	Treatment	High Blood Pressure (Hypertension)	1
3	Terminated	Prevention	Cardiac Diseases / Vascular Surgery	1
4	Completed	Treatment	Atrial Fibrillation (AF)	1
4	Completed	Treatment	High Blood Pressure (Hypertension) / Metabolic Syndromes / Obesity, Abdominal	1
4	Completed	Treatment	Polycystic Ovaries Syndrome	1
4	Recruiting	Treatment	Arterial Hypertension / Metabolic Syndromes	1
4	Unknown Status	Not Available	BMI >27 kg/m2 / BMI >30 kg/m2	1
4	Unknown Status	Treatment	Diabetic Nephropathies	1
4	Unknown Status	Treatment	High Blood Pressure (Hypertension) / Obesity, Abdominal	1
4	Unknown Status	Treatment	Schizophrenia	1
Not Available	Completed	Basic Science	Arterial Hypertension / Osteopenia	1
Not Available	Completed	Treatment	High Blood Pressure (Hypertension) / Left Ventricular Hypertrophy	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	197 – 205	MSDS
water solubility	<1 mg/mL	MSDS

Predicted Properties

Property	Value	Source
Water Solubility	0.114 mg/mL	ALOGPS
logP	1.01	ALOGPS
logP	1.54	ChemAxon
logS	-3.3	ALOGPS
pKa (Strongest Basic)	7.26	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	71.43 Å2	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	63.41 m3·mol-1	ChemAxon
Polarizability	23.57 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Diazines

Sub Class

Pyrimidines and pyrimidine derivatives

Direct Parent

Halopyrimidines

Alternative Parents

Aminopyrimidines and derivatives / Alkyl aryl ethers / Aryl chlorides / Imidazolines / Heteroaromatic compounds / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compoundsOrganochlorides / Hydrocarbon derivatives

show 2 more

Substituents

Alkyl aryl ether / Aminopyrimidine / Halopyrimidine / Aryl chloride / Aryl halide / Heteroaromatic compound / 2-imidazoline / Guanidine / Ether / AzacycleOrganic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Organopnictogen compound / Organic oxygen compound / Organic nitrogen compound / Organohalogen compound / Organochloride / Organonitrogen compound / Organooxygen compound / Hydrocarbon derivative / Aromatic heteromonocyclic compound

show 12 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

pyrimidines, organohalogen compound (CHEBI:7009)

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on October 23, 2015 14:26 / Updated on March 02, 2020 00:02